Teriflunomide for oral therapy in multiple sclerosis

Author： Papadopoulou Athina Kappos Ludwig Sprenger Till

ISSN： 1751-2433

Source： Expert Review of Clinical Pharmacology, Vol.5, Iss.6, 2012-11, pp. : 617-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Teriflunomide: a novel oral treatment for relapsing multiple sclerosis

By Sartori Arianna Carle Dawn Freedman Mark S

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 1019-1027

Informa Healthcare

Access to resources Recommend Favorite

From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis

Current Neuropharmacology, Vol. 15, Iss. 6, 2017-07 ,pp. : 874-891

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis

By Wiese Michael D

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1025-1035

Informa Healthcare

Access to resources Recommend Favorite

Oral Agents in Multiple Sclerosis

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 14, Iss. 1, 2015-03 ,pp. : 15-25

Bentham Science Publishers

Access to resources Recommend Favorite

Oral drugs for the treatment of Multiple Sclerosis

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 396-402

Govi-Verlag

Access to resources Recommend Favorite